Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176561 · ClinicalTrials.gov registry record · NA
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
A NA study of Hearing Loss and Deafness, sponsored by Gallaudet University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05176561: Recruiting NA study of Hearing Loss and Deafness, sponsored by Gallaudet University.
NCT05176561 is a NA study of Hearing Loss and Deafness that is actively recruiting participants, run by Gallaudet University. The registered enrollment target is 30 participants, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05176561, a NA study of Hearing Loss and Deafness, is actively recruiting participants, sponsored by Gallaudet University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The proposed study will investigate whether an auditory brain training program can improve cochlear implant (CI) outcomes in older post-lingually deafened CI users. The study will evaluate the potential benefit of training on speech recognition performance, psychosocial and cognitive function.
Conditions Studied
Interventions
- BEHAVIORAL Auditory-Cognitive Training
- BEHAVIORAL Non-auditory Cognitive Training
Study Locations (3)
District of Columbia
- Gallaudet University - Washington D.C.
New York
- Center for Hearing and Communication - New York
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05176561 shows while recruiting
NCT05176561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Auditory-Cognitive Training is the first listed.
NCT05176561 reports a single indexed study location in District of Columbia, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05176561 about?
NCT05176561 is a clinical study titled "Auditory-Cognitive Training to Optimize Outcomes for Older CI Users". The proposed study will investigate whether an auditory brain training program can improve cochlear implant (CI) outcomes in older post-lingually deafened CI users. The study will evaluate the potential benefit of training on speech recognition performance, psychosocial and cognitive function.
What is the current status of trial NCT05176561?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-05-01. Estimated completion is 2026-09.
What conditions does trial NCT05176561 study?
This clinical trial studies the following conditions: Hearing Loss, Deafness.
What interventions are being tested in trial NCT05176561?
The interventions under investigation include: Auditory-Cognitive Training (BEHAVIORAL), Non-auditory Cognitive Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05176561?
This trial is sponsored by Gallaudet University, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05176561 being conducted?
This trial has 3 study locations across District of Columbia, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05176561's enrollment target sits among peer trials
30 49th of 58 higher than 9 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
-
Preschool Hearing Screening
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI